Format

Send to

Choose Destination
Pediatr Blood Cancer. 2019 Mar;66(3):e27544. doi: 10.1002/pbc.27544. Epub 2018 Nov 4.

How I approach iron deficiency with and without anemia.

Author information

1
Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, Texas.
2
Texas Children's Hospital, Houston, Texas.
3
Division of Hematology/Oncology, Nationwide Children's Hospital, Columbus, Ohio.
4
Department of Pediatrics, The Ohio State University, Columbus, Ohio.

Abstract

Iron deficiency anemia remains a common referral to the pediatric hematology-oncology subspecialist. Improved understanding of iron homeostasis, including the effects of the regulatory hormone hepcidin, recent adult and pediatric clinical trial data, as well as the availability of safer formulations of intravenous iron, have resulted in additional considerations when making treatment recommendations in such patients. Young children and adolescent females remain the most commonly affected groups, but children with complex medical or chronic inflammatory conditions including comorbid gastrointestinal disorders also require special consideration.

KEYWORDS:

hepcidin; inflammation; intravenous; nutritional; therapy

PMID:
30393941
DOI:
10.1002/pbc.27544

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center